Bertani L, Ribaldone DG, Bossa F, Guerra M, et al. Reply: "Early Switching to Subcutaneous Infliximab as a Pragmatic Strategy for Optimized Inflammatory Bowel Disease Care". Inflamm Bowel Dis 2025 Dec 5:izaf264. doi: 10.1093.
PMID: 41350113